Equites Radar

TMO · Thermo Fisher Scientific Inc

Diagnostics & ResearchUnited StatesAnalyst view: Buy

$568.26

+3.02% last session

End-of-day data · updated 2026-07-28

Mildly bullish3 bullish · 2 bearish technical signals
Consensus: Buy (1.61 from 26 analysts)
To mean target: +8.8%

Market cap

$208B

Enterprise value

$246B

Trailing P/E

30.1

Forward P/E

20.4

Dividend yield

0.0%

Beta

0.87

Avg volume

2M

Employees

125K

2D change

5D change

-2.23%

10D change

5.08%

30D change

9.06%

60D change

13.72%

MTD change

9.00%

YTD change

-3.25%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)1.61
Covering analysts26
Mean price target$618.00
Low price target$510.00
Upside to mean target+8.8%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)70.3
50-day MA$494.23
200-day MA$528.99
Price vs 50-day MA+16.6%
Price vs 200-day MA+9.0%
MACD histogram3.25
Volume vs 3-month avg1.1×
52w low $437.9052w high $638.18

Analyst sentiment over time — TMO

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-07-27

Latest call per bank · past 12 months

Morgan Stanley

Overweight

$650

+14.4% vs price
▲ raised from $620Maintains · 2026-07-27

RBC Capital

Sector Perform

$580

+2.1% vs price
▲ raised from $490Maintains · 2026-07-24

Barclays

Overweight

$650

+14.4% vs price
▲ raised from $625Maintains · 2026-07-24

HSBC

Hold

$540

-5.0% vs price
▼ cut from $670Downgrade · 2026-06-03

Wells Fargo

Overweight

$615

+8.2% vs price
▼ cut from $675Maintains · 2026-05-08

Citigroup

Buy

$685

+20.5% vs price
▲ raised from $660Maintains · 2026-01-30

Goldman Sachs

Buy

$685

+20.5% vs price
▲ raised from $0.00Initiates · 2025-12-09

UBS

Neutral

$590

+3.8% vs price
▲ raised from $500Maintains · 2025-10-23

JP Morgan

Overweight

$650

+14.4% vs price
▲ raised from $600Maintains · 2025-10-09

Recent rating actions

DateFirmActionRatingPrice target
2026-07-27Piper SandlerMaintainsNeutral$510 $600
2026-07-27Morgan StanleyMaintainsOverweight$620 $650
2026-07-24RBC CapitalMaintainsSector Perform$490 $580
2026-07-24BarclaysMaintainsOverweight$625 $650
2026-07-06Evercore ISI GroupMaintainsOutperform$575 $570
2026-06-11Piper SandlerInitiatesNeutral$0.00 $510
2026-06-03HSBCDowngradeBuyHold$670 $540
2026-05-08Wells FargoMaintainsOverweight$675 $615

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-28

  • RSI (14): RSI is 70 — overbought territory; the recent run-up may be due for a pause.
  • Price vs 50-day MA: Trading 16.6% above the 50-day MA ($494.23).
  • Price vs 200-day MA: Trading 9.0% above the 200-day MA ($528.99).
  • MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
  • MACD (12,26,9): MACD histogram is positive (+3.25) — short-term momentum is improving.
  • 52-week range: Price sits between the 52-week low ($437.90) and high ($638.18).

TMO Price Chart

Loading chart for TMO

Fundamentals

Revenue (TTM)$46B
EBITDA$12B
Free cash flow$6.0B
Operating cash flow$9.0B
Book value / share$139.75
Net debt / EBITDA3.3
WACC9.0%
Revenue growth10.00%
Earnings growth9.00%

About Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

More in Diagnostics & Research

Screen TMO against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.